Friday, February 20, 2026
Symposium Agenda
Jump To A Session
REGISTRATION // EXHIBITS // BREAKFAST
7:30 AM-8:30 AM | Terrace
INDUSTRY PRODUCT THEATER
Evidence-Based Treatment for Recurrent Pericarditis
SPEAKER: Rigved Tadwalkar, MD | Pacific Heart Institute / Cedars-Sinai
TIME: 7:45 AM-8:15 AM
LOCATION: Divisible Conference Room
Session 1: Cardiomyopathy—Genotypes, Phenotypes & Endotypes
-
Welcome Remarks
Event Co-Directors:
Drs. Adler, Urey, Hong & Bui
8:30 AM -
KEYNOTE: HCM: Updates in Clinical Therapies
Ahmad Masri, MD
8: 40 AM -
Understanding Incomplete Penetrance in Cardiomyopathies – Insights from Novel Models
Eric Adler, MD
8:57 AM -
Overview of Gene Therapies
Kimberly Hong, MD
9:09 AM -
The True Guide to Precision Care: Genotype, Endotype, or Phenotype?
DISCUSSION PANEL
Drs. Masri, Adler, Hong, Bajona
9:21 AM
Session 2: The Genetic Revolution Is Here, Or Is It?
-
Genetic Testing in 2025: How Does It Change Practice List Item
Quan Bui, MD
10:00 AM -
Whole Genome Sequencing: The Future, or Always the Future?
Victoria Parikh, MD
10:12 AM -
Genetic Testing of Lipid Disorders
Harpreet Bhatia, MD
10:24 AM -
Why Aren’t We Testing More Patients? Should We?
DISCUSSION PANEL
Drs. Bui, Parikh, Bhatia, Tstimikas
10:36 AM
AM BREAK
15 Minutes
Session 3: Unraveling ATTR—Pathophysiology, Imaging & Intervention
-
Transthyretin Amyloidosis Pathophysiology: Why Is There Destabilization and What Drives Organ Infiltration?
Marcus Urey, MD
11:30 AM -
Imaging for Diagnosis and Surveillance: Can We Rely on Novel Imaging Tools to Quantify Amyloid Burden?
Brett Sperry, MD
11:42 AM -
Disease Targeted Therapies: Can Early Diagnosis and Treatment Initiation Halt Disease Progression?
Ahmad Masri, MD
11:54 AM -
Stabilizers, Silencers, or Antibodies - Which is First Line?
DISCUSSION PANEL
Drs. Urey, Sperry, Masri & Castano
Moderator: Quan Bui, MD
12:06 PM
LUNCH BREAK & POSTER PRESENTATIONS
12:41 PM-1:55 PM | Terrace
INDUSTRY PRODUCT THEATER
An Extended Overview of Attruby for ATTR-CM
SPEAKER: Marcus Urey, MD | UC San Diego
TIME: 12:45 PM-1:45 PM
LOCATION: Divisible Conference Room
ABOUT: This presentation explores transthyretin amyloid cardiomyopathy (ATTR-CM), highlighting disease pathophysiology, diagnostic considerations, and the clinical impact of transthyretin (TTR) stabilization. It reviews key efficacy and safety data for Attruby® (acoramidis) from the ATTRibute-CM Phase 3 trial, including effects on mortality, cardiovascular hospitalizations, functional capacity, quality of life, and biomarkers, along with dosing, safety, and patient support resources.
Session 4: Population Science & Economic Impact of Precision Medicine
-
KEYNOTE: Economics of Innovation – Who’s Paying and Who’s Benefiting from Precision Cardiac Care?
Robert Califf, MD
1:55 PM -
Challenges In and Strategies to Improve Rare Disease Health Technology Assessments
Daniel Ollendorf, PhD
2:12 PM -
Valuation of Rare Disease Therapeutics Using Real-World Evidence
Michael Hogarth, MD
2:24 PM -
Predicting Trajectories in Stage B Heart Failure: Insights from Machine Learning Models
Avi Yagil, PhD
2:36 PM -
Valuing Innovation
DISCUSSION PANEL
Drs. Califf, Ollendorf, Hogarth, Yagil
Moderator: Kim Hong, MD
2:48 PM
Session 5: Mechanisms and Novel Therapeutics
-
Insights into Mechanisms of Dilated Cardiomyopathy
Zoltan Arany, MD, PhD
3:23 PM -
Overview of Ex Vivo Gene Therapy – Applications for Genetic Disorders
Stephanie Cherqui, PhD
3:35 PM -
RNA: ASO, siRNA, and Gene Editing
Gene Yeo, PhD
3:47 PM -
RNA, DNA, or Protein
DISCUSSION PANEL
Drs. Hong, Cherqui, Yeo
3:59 PM
PM BREAK
15 Minutes
Session 6: Patients Are Waiting
-
Where Should We Focus Our Investments?
INDUSTRY ROUNDTABLE
Panelists: Nolan Townsend (Lexeo) • Samuel Tsimikas (Ionis) • Steven Heitner (Cytokinetics)
Moderator: Josh Schimmer, MD
4:50 PM -
Patient Perspectives: The Value of Collaborations
PATIENT CHAT
Panelists: Judy Bruner (HCM) • Julie Peacock (Heart Transplant) • Ken Friess (Amyloidosis) • Avi Yagil, PhD
5:28 PM -
Closing Remarks
Eric Adler, MD
5:54 PM
EVENT ADJOURN
6:00 PM